key: cord-0778283-izt8lch8
authors: Nikolova, Maria; Todorova, Yana; Emilova, Radoslava; Trifonova, Iva; Gladnishka, Teodora; Petrova‐Yancheva, Nina; Chervenyakova, Tatyana; Dragusheva, Elena; Popov, Georgi; Christova, Iva
title: Induction of humoral and cellular immune responses to COVID‐19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers
date: 2022-01-18
journal: J Med Virol
DOI: 10.1002/jmv.27572
sha: 898c16e2fdbefca7f8227fdca278858dbd961442
doc_id: 778283
cord_uid: izt8lch8

Installing efficient protective immunity by anti‐SARS‐CoV‐2 vaccines is the only current means to overcome coronavirus disease 2019 pandemics. The cellular and humoral immune responses induced with an messenger RNA (mRNA) (BNT162b2) or with a vector (ChAdOx1nCoV‐19) vaccine among Bulgarian healthcare workers (n = 123, aged 23–71 years) were studied in the course of 16 weeks after priming. Receptor‐binding domain (RBD)‐blocking Abs and SARS‐CoV‐2 RBD immunoglobulin A (IgA) were evaluated in parallel with interferon gamma (IFNγ)‐producing virus‐specific T cells. Both vaccines induced RBD‐blocking Abs in 100% of the participants after complete immunization while the levels of protection after a single dose largely varied (22%–98%). Advanced age had a negative impact on the level and longevity of virus‐neutralizing activity induced by one dose mRNA, but not by the vector vaccine. RBD‐binding IgA was detected in 100% of tested donors from the mRNA vaccine cohort, and in 67% of tested from the vector vaccine cohort, at least 1 month after completed immunization. One month after completing mRNA immunization, the number of IFNγ‐producing T cells correlated significantly with the levels of RBD‐specific IgA and virus‐neutralizing activity induced after priming. Enumeration of circulating virus‐specific IFNγ+ T cells is not recommended for evaluation of protective immunity as their detection may require longer stimulation beyond the firstmonth postimmunization. In conclusion, BNT162B2 and ChAdOx1nCoV‐19 induced potent and comparable humoral and cellular anti‐SARS‐CoV‐2 immune responses, peaking between 10 and 30 days after complete immunization. A single dose of any vaccine did not induce adequate protection in a great part of donors, making the shorter interval between mRNA vaccine doses preferable in the settings of increased risk of infection.

Since the end of 2019, the newly emerged SARS-CoV-2 has caused over 210 million infections leading to coronavirus disease 2019 , and over 4.4 million deaths. 1 Unlike its predecessors, SARS-CoV and MERS-CoV, SARS-CoV-2 has initiated a pandemic with no signs of self-limitation. 2 Lack of seasonality, resistance outside the host, long incubation period, and possibility of transmission before the appearance of symptoms contribute to its extensive spread.

Adaptive response to SARS-CoV-2 relies on two components: virus-neutralizing antibodies (NAbs) preventing the attachment of free virions to the ACE2 receptor-expressing host cells, and effector CD8+ and CD4+ T lymphocytes eliminating infected cells by direct or by cytokine-mediated cytotoxicity. [3] [4] [5] In addition, long-living memory T and B cells are generated, that in case of re-infection restart production of antibodies and effector T cells, and regulatory T subsets that prevent pathological effects of nonspecific activation. 6 Protective humoral and cellular immunity to SARS-CoV-2 has been demonstrated both in animal models and in human. [7] [8] [9] Virusspecific memory T cells were identified 5-17 years after MERS and SARS-CoV infections. 5, 6 Recently, SARS-CoV-2-specific bone marrow plasma cells, and persistent germinal center B cell response were reported after recovery from COVID-19, in favor of long-lived humoral immune memory. 10, 11 In the absence of specific antiviral treatment, preventive vaccines aiming to install protective immunity are the only means to limit the spread of infection and the rate of viral mutations. At the end of 2020, a nucleoside-modified messenger RNA (mRNA)-based vaccine BNT162B2 (Pfizer/BioNTech) was licensed for application in the EU, followed by the adenovirus vector-based ChAdOx1 nCoV-19 (AZD1222) (AstraZeneca). Regardless of the vaccine platform, both aimed at the full-length viral Spike (S) protein interacting with ACE2 receptors through its receptor-binding domain (RBD), and mediating viral entry. 12 The immunogenicity of vaccines is of primary scientific and public interest. COVID-19 vaccines are expected to induce high titers of virus-specific antibodies, that prevent symptomatic infection, and reduce viral shedding and transmission. In parallel, virus-specific CD4+ and CD8+ T cells recognizing immunodominant epitopes from S protein, with proper function, are critical for limiting viral replication and spread, and the instauration of memory. 3, 12 Immunogenicity data published in the course of early clinical studies of both vaccines were limited regarding the assessed parameters and the number of tested participants. 12 Most studies reported data on NAbs and virus-binding antibodies, [13] [14] [15] [16] [17] [18] and only part of them on T-cell immunity. 14, 15, 18 Various methods and modifications of standard protocols were used for evaluation of virus-specific response, producing hardly comparable relative values. Antibody and T-cell responses were measured for only a short period after the final immunization. Initial trials involved young or middle-aged healthy noninfected adults, while minority, professional or risk groups were underrepresented. 12 The application of national vaccination programs brought forward a number of issues, such as the possibility of extending the interval between the two doses of ChAdOx1 nCoV-19 (AstraZeneca), the immunogenicity of a single vaccine dose, the correlation between humoral and cellular immunity, assessed in parallel, the effects of age, professional risk or comorbidities on the efficacy and duration of immune responses.

Real-life data from particular professional and risk groups, comparing different vaccines and regimens, and assessing in parallel different parameters of humoral and cellular immunity are still lacking.

These are the first data on the immunogenicity of SARS-CoV-2 vaccines since the beginning of the national campaign in Bulgaria. Two cohorts of healthcare workers immunized with an mRNA or with a vector vaccine were followed in the course of 16 weeks after the first application. Virus neutralizing activity (VNA) and RBD-binding immunoglobulin A (IgA) were evaluated alongside virus-specific interferon gamma (IFNγ)secreting T cells, and the impact of age and co-morbidities was assessed.

This prospective longitudinal study was conducted in two cohorts. only, or PHA, and further transferred to an IFNγ-coated ELIspot 96-well plate to be processed as described above.

Quantitative data were presented as mean (±SD), and qualitative data were presented as percentages. Paired and nonpaired t tests (or the nonparametric Wilcoxon and Mann-Whitney tests when appropriate) were used to compare characteristics between groups, and Spearman's or Pearson correlation coefficient test-to evaluate the association between two or more variables, with GraphPad Prism v. 9.0.0 (GraphPad Software, LLC).

A total of 71 volunteers, 27 male, 44 female, mean age 52 years (range: 23-76), were followed after application of the mRNA vaccine (BNT162b2, Comirnaty). In this cohort 28 donors (39%) had a history of chronic condition: Hashimoto thyroiditis (n = 5), hypertension (n = 11), diabetes (n = 3), tumor (n = 2), ischemic heart disease (n = 2), sarcoidosis (n = 1), Bechterew's disease (n = 1), atopic dermatitis (n = 1), asthma (n = 1), morbus Strumpell (n = 1). Seven reported a recent (up to 3 months before priming) vaccination with influenza vaccine. One volunteer reported a mild COVID-19 infection, and one another-undefined acute viral infection in October 2020.

A total of 49 volunteers, 13 male, 36 female, mean age 49 years (range: 25-68), were followed after application of the vector vaccine 

NAbs are considered a better marker of protection, though their titers generally correlate with S-RBD binding ones. 19 VNA response to one dose mRNA vaccine (D21) correlated significantly and negatively with the age of the immunized (R = −0.6, p < 0.01) ( Figure 1D ), but was not associated with the presence of a chronic condition. In contrast, no such negative correlation was seen on D111 (data not shown). Thus, a low/absent VNA after the first dose was not necessarily associated with immune deficiency and did not preclude VNA response after a complete immunization. Although advanced age requires completion of immunization schedule on short notice, it does not impact the level or half-life of virus-neutralizing activity in peripheral blood.

Immediate protection depends strongly on the availability of SARS-CoV-2 specific IgA. 20 Therefore, RBD-specific IgA responses were evaluated in addition. As expected, one dose mRNA vaccine-induced IgA levels (mean ± SD 4.07 ± 3.1 on D21 vs.

2.1 ± 3.2 at baseline, p < 0.0001), that were further increased after complete immunization (6.05 ± 3.1 on D51, p < 0.001 as compared to D21), (Figure 2A ). Intriguingly, a subgroup of donors had significantly higher levels of RBD-specific IgA (above the mean ± SD) as compared to the rest of the group on D21 

The efficiency and longevity of virus-specific antibody response depend on the induction of cellular immunity. 3 The decline of VNA in peripheral blood is another important parameter of vaccine efficacy. Studies on BNT162b2 reported insignificant decline but data was limited to D28-D35 21 or D60 after priming. 22 We followed VNA response to the mRNA vaccine for a IgA. Therefore, routine evaluation of virus-specific T cell response in peripheral blood beyond 1 month after immunization is of no practical value. In case of an absent or inadequate humoral immune response, a modified activation protocol for detection of virus-specific T cells should be considered.

In conclusion, BNT162B2 and ChAdOx1nCoV-19 induced potent and comparable humoral and cellular anti-SARS-CoV-2 immune responses in Bulgarian healthcare workers, peaking between 10 and 30 days after complete immunization. One dose of any vaccine did not induce a substantial immune response correlating to protection for a great part of advanced age donors. Therefore, due to the shorter interval be- 

The data that support the findings of this study are available from the corresponding author upon reasonable request. Requests for access to the study data can be submitted to the corresponding author.

ORCID Iva Christova http://orcid.org/0000-0002-7878-3995

The peer review history for this article is available at https://publons. com/publon/10.1002/jmv.27572

COVID-19) Dashboard

SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview

T cell immunity to SARS-CoV-2 following natural infection and vaccination

Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines

Immunological consequences of immunization with COVID-19 mRNA vaccines: preliminary results

Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets

Correlates of protection against SARS-CoV-2 in rhesus macaques

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Derhovanessian E Concurrent human antibody and TH1 type T-cell responses 2 elicited by a COVID-19 RNA vaccine

Evolution of antibody immunity to SARS-CoV-2

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Kinetics of SARS-CoV-2 anti-s IgG after BNT162b2 vaccination

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients

Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study. The Lancet/Healthy Longevity

Immune response to COVID-19 mRNA vaccine-a pilot study

Persistence through 6 months after the second dose of mRNA-1273 Vaccine for Covid-19

Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomized trials

Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Induction of humoral and cellular immune responses to COVID-19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers

Growth 2014-2020 (Grant: BG05M2OP001-1.002-0001-C04).

The authors declare that there are no conflict of interests.

Maria Nikolova: designed the study, analyzed data, and wrote the